US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition
Time:2024-05-21 17:22:14 Source:sportViews(143)
WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Previous:Kosovo prepares a new draft law on renting prison cells to Denmark after the first proposal failed
Next:Uber and Lyft say they'll stay in Minnesota after Legislature passes driver pay compromise
You may also like
- Election 2024: Biden and Trump bypassed the Commission on Presidential Debates
- Government continues funding free period products in schools
- Release of kiwi into Te Papa
- Palmerston North businesses not sold on benefits of cycle lanes
- Red Lobster seeks bankruptcy protection after closing some restaurants
- Kaimanawa horses adoptions threatened by cost of living
- Auckland bus services disrupted by police search warrant
- Mysterious 'Big Ring' found in space 'must surely be telling us something'
- Messi in and Dybala out in Argentina squad for pre